News
31 March 2020

EIB finances AM-Pharma's development of acute kidney injury treatment

In:
Infrastructure
Region:
Europe

The EIB and Utrecht-based AM-Pharma have signed a €24 million financing agreement. The funds will be used to accelerate the development of the clinical stage biopharmaceutical company’s recombinant alkaline phosphatase enzyme, which is used to treat acute kidney injury (AKI). The...

Exclusive subscriber content…

If you are a TXF subscriber, please login to continue reading

Login

Not yet a subscriber? Join us today to continue accessing content without any restrictions

View our subscription options

Or to request access to TXF Intelligence contact us

Request Access

You might also like


Video
07 April 2026

Crisis in the Gulf: Sullivan & Worcester on trade under...

TXF speaks to Sullivan & Worcester partner Robert Parson about trade disputes, credit escalation and the flight to size as the crisis in the Gulf continues.

Interview
08 April 2026

Linxon’s Reisacher on working with ECAs in challenging times

Stefan Reisacher, CEO of EPC contractor Linxon, discusses how to work with ECAs in challenging conditions. Contractors need to improve communications with sub-suppliers - from...